Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gsk Investigational Site
Almagro, Argentina
Maria Ines FigueroaRecruiting - Gsk Investigational Site
Buenos Aires, Argentina
Marcelo LossoRecruiting
- Gsk Investigational Site
Francistown, Botswana
Joseph MakhemaRecruiting
- Gsk Investigational Site
Porto Alegre, Brazil
Breno Riegel SantosRecruiting - Gsk Investigational Site
Rio de Janeiro, Brazil
Beatriz Gilda GrinsztejnRecruiting - Gsk Investigational Site
São Paulo, Brazil
Jose MadrugaRecruiting - Gsk Investigational Site
São Paulo, Brazil
Ricardo VasconcelosRecruiting
- Gsk Investigational Site
Mbabane, Eswatini
Harriet Nuwagaba-BiribonwohaRecruiting
- Gsk Investigational Site
Kisumu, Kenya
Florence AweyoRecruiting
- Gsk Investigational Site
Blantyre, Malawi
Noel KayangeRecruiting - Recruiting
- Gsk Investigational Site
Lima, Peru
Jorge Gallardo CartageneRecruiting - Gsk Investigational Site
Lima, Peru
Javier ValenciaRecruiting - Gsk Investigational Site
Lima, Peru
Milagros Matta AguirreRecruiting - Gsk Investigational Site
Lima, Peru
Yvett PinedoRecruiting - Gsk Investigational Site
Piura, Peru
Wilfredo CasapiaRecruiting
- Gsk Investigational Site
Cape Town, South Africa
Completed - Gsk Investigational Site
City of Cape Town, South Africa
Steven InnesRecruiting - Gsk Investigational Site
City of Cape Town, South Africa
Keren MiddelkoopRecruiting - Gsk Investigational Site
City of Johannesburg, South Africa
Elizabeth RoosRecruiting - Gsk Investigational Site
Durban, South Africa
Villeshni AsariRecruiting - Gsk Investigational Site
Durban, South Africa
Elizabeth SpoonerRecruiting - Gsk Investigational Site
Isipingo, South Africa
Nishanta SinghRecruiting - Gsk Investigational Site
Sol Plaatjie, South Africa
Ravindre PanchiaRecruiting
- Gsk Investigational Site
Chiang Mai, Chiang Mai, Thailand
Suwat ChariyalertsakRecruiting - Gsk Investigational Site
Pathum Wan, Thailand
Nittaya PhanuphakRecruiting
- Gsk Investigational Site
Entebbe, Uganda
Juliet MpendoRecruiting - Gsk Investigational Site
Kampala, Uganda
Patricia Ntege NahiryaRecruiting - Gsk Investigational Site
Kampala, Uganda
Clemensia NakabiitoRecruiting
- Gsk Investigational Site
Chitungwiza, Zimbabwe
Nyaradzo MgodiRecruiting - Gsk Investigational Site
Chitungwiza, Zimbabwe
Patricia MandimaRecruiting - Gsk Investigational Site
Chitungwiza, Zimbabwe
Tariro Chawana - MutingwendeRecruiting - Gsk Investigational Site
Harare, Zimbabwe
Felix Muhlanga (Mhlanga)Recruiting - Gsk Investigational Site
Harare, Zimbabwe
Pamela MukwekwerereRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 May 2024
- Primary completion
- 1 Jan 2029
- Completion
- 1 Jan 2029
- Last update posted
- 22 Dec 2025
- Registered enrollment
- 3,508
- Registry id
- NCT06134362
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.